PharmaCyte Biotech, Inc. (PMCB)
PMCB moved a median of 0.00% 30 minutes after news, and -0.66% by the close. How PMCB actually reacts to news — the realized, point-in-time move the market made, measured across 84 labeled events over the last three years with zero look-ahead.
PMCB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 23% | 64 |
| 30-min | 0.00% | 41% | 80 |
| 60-min | 0.00% | 42% | 83 |
| to close | -0.66% | 45% | 83 |
| Middle 50% of PMCB reactions | -0.95% to +2.04% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 84 |
Half of all PharmaCyte Biotech, Inc. news events land between -0.95% and +2.04% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when PMCB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PMCB's baseline. Nothing else.
Recent PMCB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K PharmaCyte Biotech, Inc. For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 10-Q PharmaCyte Biotech, Inc. For: Jul 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.95% | -2.61% | |
| Form 10-Q PharmaCyte Biotech, Inc. For: Jul 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.45% | -0.88% | |
| Form 10-K PharmaCyte Biotech, Inc. For: Apr 30 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +2.48% | |
| Form 8-K PharmaCyte Biotech, Inc. For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | -0.95% | +1.51% | |
| Form 10-Q PharmaCyte Biotech, Inc. For: Jan 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.78% | -0.82% | |
| Form ARS PharmaCyte Biotech, Inc. For: Apr 30 | SEC filing · Form ARS | SEC EDGAR | +9.45% | -2.39% | |
| Form DEF 14A PharmaCyte Biotech, Inc. For: Mar 30 | SEC filing · Form DEF | SEC EDGAR | -7.39% | -9.61% | |
| Form PRE 14A PharmaCyte Biotech, Inc. For: Mar 30 | SEC filing · Form PRE | SEC EDGAR | -0.85% | +3.42% | |
| Form 10-Q PharmaCyte Biotech, Inc. For: Oct 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.42% | +2.88% | |
| Form NT 10-Q PharmaCyte Biotech, Inc. For: Oct 31 | SEC filing · Form NT | SEC EDGAR | +1.98% | +4.40% | |
| Form 8-K PharmaCyte Biotech, Inc. For: Dec 01 | SEC filing · Form 8-K | SEC EDGAR | -0.02% | -1.71% | |
| PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment | Press release | Business Wire | +11.89% | +34.85% | |
| Form 8-K/A PharmaCyte Biotech, Inc. For: Sep 02 | SEC filing · Form 8-K | SEC EDGAR | -0.85% | -5.62% | |
| Form 8-K PharmaCyte Biotech, Inc. For: Oct 30 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.35% | |
| Form DEF 14A PharmaCyte Biotech, Inc. For: Oct 30 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -0.98% | |
| Form EFFECT PharmaCyte Biotech, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -2.79% | -2.97% | |
| Form PRE 14A PharmaCyte Biotech, Inc. For: Oct 30 | SEC filing · Form PRE | SEC EDGAR | -3.74% | -9.25% | |
| Form S-3 PharmaCyte Biotech, Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.04% | -4.82% | |
| Form 10-Q PharmaCyte Biotech, Inc. For: Jul 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -6.48% | |
| Form 8-K PharmaCyte Biotech, Inc. For: Sep 02 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +16.50% | |
| Form D PharmaCyte Biotech, Inc. | SEC filing · Form D | SEC EDGAR | +0.00% | -0.66% | |
| PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications | Press release | Business Wire | -3.00% | -6.85% | |
| PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing | Press release | Business Wire | -1.94% | — | |
| Form 8-K PharmaCyte Biotech, Inc. For: Aug 17 | SEC filing · Form 8-K | SEC EDGAR | +4.84% | +13.85% | |
| PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors | Press release | Business Wire | +4.84% | +13.85% | |
| Form 10-K PharmaCyte Biotech, Inc. For: Apr 30 | SEC filing · Form 10-K | SEC EDGAR | -1.17% | +5.53% | |
| Form NT 10-K PharmaCyte Biotech, Inc. For: Apr 30 | SEC filing · Form NT | SEC EDGAR | +0.00% | +0.49% | |
| Form 8-K PharmaCyte Biotech, Inc. For: Apr 24 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.27% | |
| Form 10-Q PharmaCyte Biotech, Inc. For: Jan 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.63% | -5.06% | |
| Form ARS PharmaCyte Biotech, Inc. For: Apr 30 | SEC filing · Form ARS | SEC EDGAR | — | -1.68% | |
| Form DEF 14A PharmaCyte Biotech, Inc. For: Apr 24 | SEC filing · Form DEF | SEC EDGAR | — | -1.68% | |
| Form DEFA14A PharmaCyte Biotech, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | — | -1.68% | |
| Form 8-K PharmaCyte Biotech, Inc. For: Feb 21 | SEC filing · Form 8-K | SEC EDGAR | — | -0.58% | |
| Form 10-Q PharmaCyte Biotech, Inc. For: Oct 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -1.74% | |
| Form S-8 PharmaCyte Biotech, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +0.00% | |
| Form 10-Q PharmaCyte Biotech, Inc. For: Jul 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +5.03% | |
| Form NT 10-Q PharmaCyte Biotech, Inc. For: Jul 31 | SEC filing · Form NT | SEC EDGAR | +0.00% | +5.03% | |
| Form 10-K PharmaCyte Biotech, Inc. For: Apr 30 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +3.28% | |
| Form NT 10-K PharmaCyte Biotech, Inc. For: Apr 30 | SEC filing · Form NT | SEC EDGAR | +0.06% | +2.56% | |
| Form 8-K PharmaCyte Biotech, Inc. For: May 20 | SEC filing · Form 8-K | SEC EDGAR | — | -0.47% | |
| PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease | Press release | Business Wire | +3.87% | +0.97% | |
| Form 8-K PharmaCyte Biotech, Inc. For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | — | +0.47% | |
| Form ARS PharmaCyte Biotech, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | -2.07% | |
| Form DEF 14A PharmaCyte Biotech, Inc. For: Apr 29 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -2.07% | |
| Form 10-Q PharmaCyte Biotech, Inc. For: Jan 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.44% | +6.47% | |
| Form 10-Q PharmaCyte Biotech, Inc. For: Oct 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -3.56% | |
| Form 8-K PharmaCyte Biotech, Inc. For: Nov 20 | SEC filing · Form 8-K | SEC EDGAR | -2.62% | -0.86% | |
| Form 8-K PharmaCyte Biotech, Inc. For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.50% | |
| PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. | Press release | Business Wire | — | -1.92% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PMCB section they belong to.
Where else PMCB is measured.
PMCB earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Knight Therapeutics Inc (GUD_TSE) | 84 | 0.00% | 40% |
| Molecular Templates, Inc. (MTEM) | 84 | -0.48% | 39% |
| ABATTIS BIOCEUTICALS ORD (ATTBF) | 83 | -0.24% | 41% |
| Intercept Pharmaceuticals, Inc. (ICPT) | 83 | +0.09% | 68% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is PharmaCyte Biotech, Inc.'s median reaction calculated?
Every labeled PMCB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 84 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of PMCB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PMCB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.